A Closer Look at 9 Analyst Recommendations For CG Oncology
Portfolio Pulse from Benzinga Insights
Nine analysts have provided varied opinions on CG Oncology (NASDAQ:CGON) over the past quarter, with the majority being bullish. The average 12-month price target is $68.33, slightly down from the previous $69.67. Key analysts from firms like B of A Securities, HC Wainwright & Co., and Goldman Sachs have maintained or raised their ratings, with price targets ranging from $50.00 to $75.00. CG Oncology is a late-stage clinical biopharmaceutical company focused on bladder cancer treatments, showing strong revenue growth but facing profitability challenges.
June 28, 2024 | 3:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
CG Oncology has received predominantly bullish ratings from analysts, with a 12-month price target averaging $68.33. The company shows strong revenue growth but faces challenges in profitability.
The majority of analysts have given bullish ratings, indicating positive sentiment. The average price target is slightly down but still reflects optimism. Strong revenue growth supports a positive outlook, though profitability challenges may temper expectations.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100